Sera Prognostics (SERA) Set to Post Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is expected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.14) per share and revenue of $0.07 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.07 million. On average, analysts expect Sera Prognostics to post ($0.62) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Sera Prognostics Price Performance

Shares of NASDAQ:SERA traded up $0.02 during midday trading on Wednesday, hitting $2.07. The company had a trading volume of 248 shares, compared to its average volume of 44,034. The company has a market cap of $81.62 million, a price-to-earnings ratio of -3.09 and a beta of 1.06. Sera Prognostics has a 12-month low of $1.56 and a 12-month high of $3.85. The company has a fifty day moving average of $2.05 and a two-hundred day moving average of $2.17.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sera Prognostics currently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total transaction of $40,278.00. Following the transaction, the chief executive officer owned 844,870 shares of the company’s stock, valued at $1,689,740. The trade was a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 39,661 shares of company stock valued at $79,563. Corporate insiders own 11.30% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company uses proteomics, bioinformatics and clinical data to develop diagnostic and prognostic products designed to identify risks associated with pregnancy complications.

Its lead product is the PreTRM test, a blood-based test intended to assess a pregnant woman’s risk of spontaneous preterm birth in a singleton pregnancy. The test measures specific protein biomarkers and is designed to provide physicians with information that may support risk assessment, patient management and care planning during pregnancy.

Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics primarily serves the U.S.